OBJECTIVE: To assess the toxicity and effectiveness of once-weekly administration of topotecan (Hycamtin; GlaxoSmithKline) for relapsed ovarian and primary peritoneal cancer. METHODS: Twenty-three patients with recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal carcinoma (PPC) previously exposed to at least one line of platinum-based chemotherapy were treated with IV weekly topotecan as a 30-min bolus at a starting dose of 4 mg/m(2) administered weekly for 3 weeks in a 28-day cycle. RESULTS: The patients' median age was 62 years (42-83). Thirteen women (56.5%) were defined as having platinum-sensitive and 10 (43.5%) as having platinum-resistant disease. Altogether, 88 cycles were administered for a total of 264 weekly treatments, with a median of four courses (range 2-6). There were no treatment delays. The main bone marrow toxicity was grade II and III thrombocytopenia, necessitating dose reduction in four patients (17.4%) and treatment cessation in one patient. The most frequent nonhematologic toxicity was fatigue (nine patients, 39.1%). There were four complete responses (17.4%, three in the platinum-sensitive and one in the platinum-resistant patients) and seven (30.4%) partial responses, for an overall response rate of 47.8%. The ORR was similar in platinum-sensitive and platinum-resistant patients (47.8% and 52.2%, respectively). The median progression-free survival was 4.9 months with a mean survival time of 11.59 months. Two women sustained complete response lasting >6 months. CONCLUSION: Topotecan given as a weekly bolus is a highly active and well-tolerated treatment regimen for relapsed ovarian and primary peritoneal cancer and thus deserves further evaluation.
OBJECTIVE: To assess the toxicity and effectiveness of once-weekly administration of topotecan (Hycamtin; GlaxoSmithKline) for relapsed ovarian and primary peritoneal cancer. METHODS: Twenty-three patients with recurrent or persistent epithelial ovarian cancer (EOC) and primary peritoneal carcinoma (PPC) previously exposed to at least one line of platinum-based chemotherapy were treated with IV weekly topotecan as a 30-min bolus at a starting dose of 4 mg/m(2) administered weekly for 3 weeks in a 28-day cycle. RESULTS: The patients' median age was 62 years (42-83). Thirteen women (56.5%) were defined as having platinum-sensitive and 10 (43.5%) as having platinum-resistant disease. Altogether, 88 cycles were administered for a total of 264 weekly treatments, with a median of four courses (range 2-6). There were no treatment delays. The main bone marrow toxicity was grade II and III thrombocytopenia, necessitating dose reduction in four patients (17.4%) and treatment cessation in one patient. The most frequent nonhematologic toxicity was fatigue (nine patients, 39.1%). There were four complete responses (17.4%, three in the platinum-sensitive and one in the platinum-resistant patients) and seven (30.4%) partial responses, for an overall response rate of 47.8%. The ORR was similar in platinum-sensitive and platinum-resistant patients (47.8% and 52.2%, respectively). The median progression-free survival was 4.9 months with a mean survival time of 11.59 months. Two women sustained complete response lasting >6 months. CONCLUSION:Topotecan given as a weekly bolus is a highly active and well-tolerated treatment regimen for relapsed ovarian and primary peritoneal cancer and thus deserves further evaluation.
Authors: S John Weroha; Ann L Oberg; Katie L Allen Ziegler; Shaker R Dakhilm; Kendrith M Rowland; Lynn C Hartmann; Dennis F Moore; Gary L Keeney; Prema P Peethambaram; Paul Haluska Journal: Gynecol Oncol Date: 2011-04-22 Impact factor: 5.482
Authors: Robert Morris; Ronald D Alvarez; Stephen Andrews; John Malone; Christopher Bryant; Lance K Heilbrun; Daryn Smith; Veronica Schimp; Adnan Munkarah Journal: Gynecol Oncol Date: 2008-04-14 Impact factor: 5.482
Authors: Steven F Powell; Amer Beitinjaneh; Mathewos Tessema; Robin L Bliss; Robert A Kratzke; Joseph Leach; Arkadiusz Z Dudek Journal: Clin Lung Cancer Date: 2013-06-28 Impact factor: 4.785
Authors: Amit M Oza; Ursula A Matulonis; Angeles Alvarez Secord; John Nemunaitis; Lynda D Roman; Sarah P Blagden; Susana Banerjee; William P McGuire; Sharad Ghamande; Michael J Birrer; Gini F Fleming; Merry Jennifer Markham; Hal W Hirte; Diane M Provencher; Bristi Basu; Rebecca Kristeleit; Deborah K Armstrong; Benjamin Schwartz; Patricia Braly; Geoff D Hall; Kenneth P Nephew; Simone Jueliger; Aram Oganesian; Sue Naim; Yong Hao; Harold Keer; Mohammad Azab; Daniela Matei Journal: Clin Cancer Res Date: 2019-12-12 Impact factor: 12.531
Authors: Divya Gupta; Ricky L Owers; Mimi Kim; Dennis Yi-Shin Kuo; Gloria S Huang; Shohreh Shahabi; Gary L Goldberg; Mark H Einstein Journal: Gynecol Oncol Date: 2009-06 Impact factor: 5.482
Authors: Michael Eichbaum; Christine Mayer; Regina Eickhoff; Esther Bischofs; Gerhard Gebauer; Tanja Fehm; Florian Lenz; Hans-Christian Fricke; Erich Solomayer; Nikos Fersis; Marcus Schmidt; Markus Wallwiener; Andreas Schneeweiss; Christof Sohn Journal: BMC Cancer Date: 2011-10-20 Impact factor: 4.430
Authors: Martin L Ashdown; Andrew P Robinson; Steven L Yatomi-Clarke; M Luisa Ashdown; Andrew Allison; Derek Abbott; Svetomir N Markovic; Brendon J Coventry Journal: F1000Res Date: 2015-07-13